Genomic Selection Platform Market Report 2025

The genomic selection platform market size has grown rapidly in recent years. It will grow from $1.94 billion in 2024 to $2.27 billion in 2025 at a compound annual growth rate (CAGR) of 17.3%. The growth in the historic period can be linked to the expansion of agricultural biotechnology, increasing use of quantitative genetics in breeding programs, heightened focus on disease resistance in crops and livestock, growth of collaborative research initiatives, and rising challenges from disease pressures and climate variability.

The genomic selection platform market size is expected to see rapid growth in the next few years. It will grow to $4.25 billion in 2029 at a compound annual growth rate (CAGR) of 16.9%. The growth in the forecast period can be linked to rising global food demand, expansion of precision agriculture, increased emphasis on sustainable breeding practices, growth in livestock genomics, and the rise of contract breeding and genomic services. Key trends during the forecast period include advancements in next-generation sequencing (NGS), integration with digital agriculture tools, adoption of AI and machine learning, implementation of cloud-based genomic data platforms, and integration of multi-omics data.

The growing adoption of personalized medicine is expected to drive the expansion of the genomic selection platform market. Personalized medicine tailors treatment and prevention strategies based on an individual’s unique genetic makeup, lifestyle, and environment. This trend is largely fueled by advancements in genomics, which allow for the precise identification of genetic variations and the development of customized treatments. Genomic selection platforms play a critical role in supporting personalized medicine by offering precise genomic insights, enabling treatments that are specifically designed for each patient. These platforms minimize trial-and-error in therapy selection by predicting how patients will respond to different interventions, ultimately improving treatment effectiveness and patient outcomes. For example, in February 2024, the Personalized Medicine Coalition reported that the U.S. Food and Drug Administration approved 26 new personalized medicines in 2023, up from 12 in 2022. This increase highlights the growing role of personalized medicine, which is fueling the demand for genomic selection platforms.

The rise in crop yields is expected to drive growth in the genomic selection platform market. Crop yield, which refers to the amount of agricultural output produced per unit of land, is increasing due to advancements in agricultural biotechnology that improve plant genetics and resilience. Genomic selection platforms play a key role in enhancing crop yields by enabling the precise selection of high-performing plant varieties, making them essential for modern agriculture and breeding programs. These platforms reduce the time and cost associated with traditional breeding methods by offering accurate genetic predictions, which in turn boosts farm productivity and food security. For instance, in February 2024, the Department for Environment, Food and Rural Affairs reported that the UK's cereal production reached 24.3 million tonnes in 2022, an 8% increase compared to 2021. This rise in crop yields further underscores the growing importance of genomic selection platforms in agriculture.

Leading companies in the genomic selection platform market are increasingly focusing on developing innovative solutions such as targeted sequencing platforms to improve trait prediction and accelerate breeding programs. Targeted sequencing platforms are genomic technologies that focus on sequencing specific regions of the genome, rather than sequencing the entire genome. For example, in October 2024, Element Biosciences launched Trinity, a breakthrough targeted sequencing platform designed to streamline exome capture by integrating traditionally complex steps into its AVITI System. The platform eliminates the need for specialized equipment, reduces manual work by up to five hours, and offers a one-hour hybridization option for same-day results, making it highly suitable for time-sensitive studies. Trinity can be expanded to support custom panels for various applications, including oncology, respiratory diseases, and minimal residual disease (MRD), offering faster, more cost-effective, and accessible sequencing. This marks a significant advancement in exome capture technology.

Major players in the genomic selection platform market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., GE Healthcare Technologies Inc., Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., MGI Tech Co. Ltd., Azenta Inc., 10x Genomics Inc., Oxford Nanopore Technologies plc, Ultima Genomics Inc., Element Biosciences Inc., DNAnexus Inc., Deep Genomics Inc., Epigene Labs Inc., Quotient Therapeutics Inc., Evogene Ltd., Nebula Genomics Inc., Verinomics Inc., InEdita Bio Inc., GenEmbryomics Inc., and Enigma Genomics Inc.

North America was the largest region in the genomic selection platform market in 2024. The regions covered in genomic selection platform report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the genomic selection platform market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

A genomic selection platform is a technology-driven system that leverages genome-wide genetic information to predict the performance or breeding potential of plants, animals, or microorganisms. It accelerates selective breeding by identifying individuals with the most desirable traits early, minimizing the need for prolonged traditional evaluation cycles. The platform integrates high-throughput genotyping, statistical modeling, and predictive algorithms to enable efficient, informed selection decisions.

The primary components of a genomic selection platform are software, hardware, and services. Software includes specialized computational tools and applications designed to process and analyze large-scale genomic data to support breeding programs. It can be implemented through on-premises or cloud-based systems and finds applications in plant breeding, animal breeding, human genomics, and more. Key end-users comprise research institutions, biotechnology firms, agricultural organizations, and other stakeholders.

The genomic selection platform market research report is one of a series of new reports that provides genomic selection platform market statistics, including the genomic selection platform industry global market size, regional shares, competitors with the genomic selection platform market share, detailed genomic selection platform market segments, market trends, and opportunities, and any further data you may need to thrive in the genomic selection platform industry. This genomic selection platform market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The genomic selection platform market consists of revenues earned by entities by providing services such as genotyping, phenotyping, data analysis and interpretation, predictive modeling, breeding program management, and consulting services. The market value includes the value of related goods sold by the service provider or included within the service offering. The genomic selection platform market also includes sales of genotyping platforms, sequencing platforms, bioinformatics software, data analysis tools, marker-assisted selection tools, DNA extraction kits, and high-throughput genotyping assays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.